Here's what interactive, virtual events to log on to this month. Katleho Seisa/Getty Images

Going into April, the city of Houston has another month at least of working from home, hopping on calls, and setting up video chats — but you don't have to go through this all alone.

Here are over 10 Houston innovation events you can attend virtually via online meetings. Be sure to register in advance, as most will send an access link ahead of the events.

April 1 — Social Entrepreneurship Meetup

Impact Hub Houston is bringing this monthly meetup online. Registrants will receive an email with the link to attend the Zoom meeting.


Details: The event is at 5:30 pm on Wednesday, April 1. Learn more.

April 2 — Considerations for Emerging Companies in the COVID-19 Era

A group of experts will discuss how the coronavirus and all its resulting complications will affect startups.

Details: The event is at 2 pm on Thursday, April 2. Learn more.

April 3 — UH's Red Labs Pitch Madness

You are invited to watch the final round of Pitch Madness, a pitch competition for UH students. Students will give a four minute pitch and be asked questions about their startup idea by judges. You can attend digitally the finals and watch students pitch at bit.ly/pitchmadness_finals.

Details: The event is at 1 pm on Friday, April 3. Learn more.

April 7 — CARES Act and Managing your Startup through the COVID Crisis

Carolyn Rodz, CEO of Alice, and Aziz Gilani, managing director of Mercury Fund, answer tech startups' questions about the CARES Act. Zoom link will be sent to attendee's prior to the event.

Details: The event is at 4 pm on Tuesday, April 7. Learn more.

April 8 — Startups & Sustainability - How to Make a Profit and Impact

Join as General Assembly brings together entrepreneurs in sustainability to examine how business and tech can be a force for good. Hear from leaders who will share their insights into how industry can impact the environment. Event will be hosted via Zoom, and registrants will be sent a link to attend.

Details: The event is at 5:45 pm on Wednesday, April 8. Learn more.

April 9 — Out of the Lab & Into the Newsroom: Media 101

This JLABs webinar will discuss trends in the media world, how these impact best outreach practices, and tips for designing a successful media campaign.

Details: The event is at 9 am on Thursday, April 9. Learn more.

April 9 — Webinar: In Today's Market - Do Patents Even Matter?

Inventors and business professionals are asked to review the claims of their patent application before it is filed. This step is THE critical step that is supposed to ensure that the claims will protect their invention. The decision you make here determines if you will be part of the 97% of all patents that never recoup the cost of filing them. This event is virtual and a Zoom link will be emailed on the day of the event.

Details: The event is at noon on Thursday, April 9. Learn more.

April 13-16 — Capital Factory's Founders Academy Essentials

Amongst all the excitement of running a startup is a lot of hard work and stressful decisions. Founders Academy Essentials is a 4-day lunch-n-learn curriculum designed specifically for driven entrepreneurs that are passionate about their business potential.

Details: The event is from Monday, April 13, to Thursday, April 16. Learn more.

April 14 — Black in Tech Summit

Capital Factory welcomes you to its 2nd Annual Black In Tech Summit. We're dedicated to increasing diversity in the tech community and making our coworking space an inclusive environment for people of all backgrounds and identities.

Details: The event is at noon on Tuesday, April 14. Learn more.

April 21 — Don’t Go Pitching in the Dark: How to Navigate Investor Interactions

In this webinar, experts of the craft will share practical tips on becoming more effective in communicating your story to investors, increasing your chances of successful fundraising.

Details: The event is at 9 am on Tuesday, April 21. Learn more.

April 21 — Employable in 2030: Closing the skills gap.

What jobs will exist in 2030? Come along and hear from a panel of industry leaders on how to stay relevant in the rapidly changing space for 2030 and beyond. Event will be hosted via Zoom, and registrants will be sent a link to attend.

Details: The event is at 7 pm on Tuesday, April 21. Learn more.

April 22 — Ion Startup Demo Day (Virtual Edition)

Top tier mentors, local investors, and personalized pitch feedback for participating startups -- nothing's changed but the address. Whether you're a serial entrepreneur or just looking to get involved in the community, this event is for YOU.

Details: The event is at 6 pm on Wednesday, April 22. Learn more.

------

For more virtual events, check out Houston Exponential's calendar.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.